2024-03-29T14:09:21Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02012414
2023-08-03T05:36:27Z
1642838163960:1642838338003
1642838403551:1642838407795
Triple primary cancer of the head and neck, skin and prostate : A case report and literature review
Maruyama, Nobuyuki
Nakasone, Toshiyuki
Arakaki, Osao
Matsumoto, Hirofumi
Maruyama, Tessho
Matayoshi, Akira
Goto, Takahiro
Saito, Seiichi
Yoshimi, Naoki
Arasaki, Akira
Nishihara, Kazuhide
head and neck cancer
second primary
skin cancer
prostate cancer
2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography
multiple primary neoplasms
Second primary cancer (SPC) is an important prognostic factor for patients with head and neck cancer (HNC); therefore, the association between the prognosis and development of SPC has been well‑reported. The use of 2‑[18F]‑fluoro‑2‑deoxy‑D‑glucose‑positron emission tomography (FDG‑PET) is valuable to examine cancer stage, evaluate treatment responses and investigate suspected relapses or metastases. In the present study, the case of a male patient who was diagnosed with three primary cancer types, including well to moderately differentiated squamous cell carcinoma (SCC) of the mandible, axillary cutaneous poorly differentiated SCC and prostate adenocarcinoma, was described. Among these, mandible cancer was the first diagnosed when the patient was 70 years of age. Synchronous skin and prostate cancer (PRC) types then developed 3 years later. To the best of our knowledge, this is the first report of the aforementioned combination of cancer types. Postoperative FDG‑PET was not performed as no lesions of recurrence or metastases of mandible cancer were found. Three years later, the PRC was asymptomatic and was incidentally detected by FDG‑PET performed for a preoperative evaluation of skin cancer. It was indicated that FDG‑PET could be utilized in patients with HNC due to there being no accurate FDG‑PET protocol to detect SPC over a long‑term follow‑up.
論文
http://purl.org/coar/resource_type/c_6501
Spandidos Publications
2018-10
VoR
http://hdl.handle.net/20.500.12000/45978
1792-1074
1792-1082
Oncology Letters
4
16
5256
5249
eng
https://doi.org/10.3892/ol.2018.9294
https://doi.org/10.3892/ol.2018.9294
open access
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
https://creativecommons.org/licenses/by-nc-nd/4.0/